Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Circulating tumor DNA enables sensitive and universally applicable MRD monitoring in AML

Tian Yi Zhang, MD, PhD, Stanford Cancer Institute, Stanford , CA, presents data on the use of circulating tumor DNA (ctDNA) for measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML), which allows for personalized and bespoke monitoring of the disease. Dr Zhang discusses this in the context of the updated European LeukemiaNet (ELN) guidelines for MRD, and highlights the potential of ctDNA-MRD to predict relapse-free survival and overall survival. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.